These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 38411391)

  • 1. Advancing lifelong precision medicine for cardiovascular diseases through gut microbiota modulation.
    Shi B; Li H; He X
    Gut Microbes; 2024; 16(1):2323237. PubMed ID: 38411391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases.
    Sanchez-Rodriguez E; Egea-Zorrilla A; Plaza-Díaz J; Aragón-Vela J; Muñoz-Quezada S; Tercedor-Sánchez L; Abadia-Molina F
    Nutrients; 2020 Feb; 12(3):. PubMed ID: 32110880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation.
    Rahman MM; Islam F; -Or-Rashid MH; Mamun AA; Rahaman MS; Islam MM; Meem AFK; Sutradhar PR; Mitra S; Mimi AA; Emran TB; Fatimawali ; Idroes R; Tallei TE; Ahmed M; Cavalu S
    Front Cell Infect Microbiol; 2022; 12():903570. PubMed ID: 35795187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspective: Leveraging the Gut Microbiota to Predict Personalized Responses to Dietary, Prebiotic, and Probiotic Interventions.
    Gibbons SM; Gurry T; Lampe JW; Chakrabarti A; Dam V; Everard A; Goas A; Gross G; Kleerebezem M; Lane J; Maukonen J; Penna ALB; Pot B; Valdes AM; Walton G; Weiss A; Zanzer YC; Venlet NV; Miani M
    Adv Nutr; 2022 Oct; 13(5):1450-1461. PubMed ID: 35776947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on gut microbiota in cardiovascular diseases.
    Qian B; Zhang K; Li Y; Sun K
    Front Cell Infect Microbiol; 2022; 12():1059349. PubMed ID: 36439214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential impact of gut microbiota on your health:Current status and future challenges.
    Sirisinha S
    Asian Pac J Allergy Immunol; 2016 Dec; 34(4):249-264. PubMed ID: 28042926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut Microbiota-Targeted Interventions in the Management of Chronic Kidney Disease.
    Sumida K; Pierre JF; Yuzefpolskaya M; Colombo PC; Demmer RT; Kovesdy CP
    Semin Nephrol; 2023 Mar; 43(2):151408. PubMed ID: 37619529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review.
    Dai Y; Shen Z; Khachatryan LG; Vadiyan DE; Karampoor S; Mirzaei R
    Pathol Res Pract; 2023 Sep; 249():154740. PubMed ID: 37567034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probiotics, gut microbiome, and cardiovascular diseases: An update.
    Dosh L; Ghazi M; Haddad K; El Masri J; Hawi J; Leone A; Basset C; Geagea AG; Jurjus R; Jurjus A
    Transpl Immunol; 2024 Apr; 83():102000. PubMed ID: 38262540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the gut microbiota in health and cardiovascular diseases.
    Wang L; Wang S; Zhang Q; He C; Fu C; Wei Q
    Mol Biomed; 2022 Oct; 3(1):30. PubMed ID: 36219347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Diseases of Developmental Origins: Preventive Aspects of Gut Microbiota-Targeted Therapy.
    Hsu CN; Hou CY; Hsu WH; Tain YL
    Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine learning for data integration in human gut microbiome.
    Li P; Luo H; Ji B; Nielsen J
    Microb Cell Fact; 2022 Nov; 21(1):241. PubMed ID: 36419034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbes in cardiovascular diseases and their potential therapeutic applications.
    Jin L; Shi X; Yang J; Zhao Y; Xue L; Xu L; Cai J
    Protein Cell; 2021 May; 12(5):346-359. PubMed ID: 32989686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-microbiota interactions: an emerging priority for precision medicine.
    Zhao Q; Chen Y; Huang W; Zhou H; Zhang W
    Signal Transduct Target Ther; 2023 Oct; 8(1):386. PubMed ID: 37806986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Gut Microbiome to Treat Cardiometabolic Disease.
    Theofilis P; Vlachakis PK; Oikonomou E; Tsioufis K; Tousoulis D
    Curr Atheroscler Rep; 2024 Feb; 26(2):25-34. PubMed ID: 38180642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiome miracles and their pioneering advances and future frontiers in cardiovascular disease.
    Safdar M; Ullah M; Hamayun S; Wahab A; Khan SU; Abdikakhorovich SA; Haq ZU; Mehreen A; Naeem M; Mustopa AZ; Hasan N
    Curr Probl Cardiol; 2024 Sep; 49(9):102686. PubMed ID: 38830479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment.
    Koszewicz M; Jaroch J; Brzecka A; Ejma M; Budrewicz S; Mikhaleva LM; Muresanu C; Schield P; Somasundaram SG; Kirkland CE; Avila-Rodriguez M; Aliev G
    Pharmacol Res; 2021 Feb; 164():105277. PubMed ID: 33166735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in modulation of cardiovascular diseases by the gut microbiota.
    Masenga SK; Hamooya B; Hangoma J; Hayumbu V; Ertuglu LA; Ishimwe J; Rahman S; Saleem M; Laffer CL; Elijovich F; Kirabo A
    J Hum Hypertens; 2022 Nov; 36(11):952-959. PubMed ID: 35469059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management?
    Mehmood K; Moin A; Hussain T; Rizvi SMD; Gowda DV; Shakil S; Kamal MA
    Folia Microbiol (Praha); 2021 Dec; 66(6):897-916. PubMed ID: 34699042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota and cardiovascular diseases axis.
    Moldovan DC; Ismaiel A; Fagoonee S; Pellicano R; Abenavoli L; Dumitrascu DL
    Minerva Med; 2022 Feb; 113(1):189-199. PubMed ID: 33969961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.